What this is
- How it works
- How it works isn't classified yet
- Tested for
- Type 2 Diabetes (2 trials), Diabetes Mellitus, Type 2 (2 trials), Type 2 Diabetes Mellitus, Diabetes Mellitus
- Main trialPhase 3
- “The purpose of this study is to evaluate efficacy and safety of SHR-3167 versus Insulin glargine in insulin-naive type 2 diabetes inadequately controlled on non-insulin anti-diabetic drugs. The hypothesis is that SHR-3167 is non-inferior to insulin glargine in the change of HbA1c from baseline after 26 weeks of treatment.”In the company’s words, NCT07920939 on ClinicalTrials.gov
Other drugs for Type 2 Diabetes
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
- HDM1002Huadong Medicine · Phase 3
Coming up5
- DecPhase 2 trial completes · ClinicalTrials.gov
- DecPhase 1 trial completes · ClinicalTrials.gov
- Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- Jan 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Oct 2027 | Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes | |
| Phase 3Not yet recruiting | Jan 2028 | A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin | |
| Phase 2Active, not recruiting | Feb 2026 | A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs | |
| Phase 2Active, not recruiting | Dec 2026 | A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents | |
| Phase 1Recruiting | Dec 2026 | A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection | |
| Phase 1Recruiting | Mar 2027 | A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes | |
| Phase 2Completed | 22 Apr 2026 | Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects | |
| Phase 1Unknown | 25 Jan 2024 | A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes | |
| Phase 1Completed | 12 Jul 2024 | To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026